[CAS NO. 1655501-53-3] Fremanezumab
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1655501-53-3]
Store
Catalog
HY-P99019
Brand
MCE
CAS
1655501-53-3
DESCRIPTION [1655501-53-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Fremanezumab] |
For research use only. We do not sell to patients.
Summary
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP) . CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03303105 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
January 4, 2018 | Phase 3 |
| NCT04628429 | Medical University of Vienna |
Episodic Migraine|Chronic Migraine
|
October 1, 2020 | |
| NCT04530110 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
September 16, 2020 | Phase 3 |
| NCT03347188 | Teva Branded Pharmaceutical Products R&D, Inc. |
Post-Traumatic Headache
|
December 18, 2017 | Phase 2 |
| NCT05458011 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
August 23, 2022 | Phase 3 |
| NCT03303079 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
December 19, 2017 | Phase 2|Phase 3 |
| NCT03539393 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
||
| NCT02945046 | Teva Branded Pharmaceutical Products R&D, Inc. |
Episodic Cluster Headache
|
January 19, 2017 | Phase 3 |
| NCT05284019 | H. Lundbeck A+S |
Migraine
|
March 4, 2022 | Phase 4 |
| NCT02629861 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
March 23, 2016 | Phase 3 |
| NCT04334408 | Mayo Clinic |
Cadasil|Migraine
|
December 2021 | Phase 2 |
| NCT03107052 | Teva Branded Pharmaceutical Products R&D, Inc. |
Cluster Headache
|
April 27, 2017 | Phase 3 |
| NCT04041284 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine|Major Depressive Disorder
|
September 13, 2019 | Phase 4 |
| NCT03308968 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine Prophylaxis
|
October 13, 2017 | Phase 3 |
| NCT03303092 | Otsuka Pharmaceutical Co., Ltd. |
Migraine
|
December 19, 2017 | Phase 2|Phase 3 |
| NCT04693533 | Beth Israel Deaconess Medical Center|Teva Pharmaceuticals USA |
Migraine Disorders|Sleep Disorder
|
July 29, 2021 | Phase 4 |
| NCT04464707 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
July 30, 2020 | Phase 3 |
| NCT03965091 | Teva Branded Pharmaceutical Products R&D, Inc. |
Fibromyalgia
|
May 31, 2019 | Phase 2 |
| NCT02638103 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
February 26, 2016 | Phase 3 |
| NCT05342493 | Otsuka Pharmaceutical Co., Ltd. |
Migraine Disorders
|
April 20, 2022 | |
| NCT02621931 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
March 22, 2016 | Phase 3 |
| NCT05281770 | Austrian Migraine Registry Collaboration|Medical University of Vienna|Medical University Innsbruck|Austrian Headache Society |
Migraine|Migraine With Aura|Migraine Without Aura|Chronic Migraine|Episodic Migraine
|
October 1, 2022 | |
| NCT02673567 | Teva Branded Pharmaceutical Products R&D, Inc. |
Pharmacokinetics
|
March 31, 2016 | Phase 1 |
| NCT04447729 | Teva Branded Pharmaceutical Products R&D, Inc. |
Interstitial Cystitis
|
October 15, 2020 | Phase 2 |
| NCT02964338 | Teva Branded Pharmaceutical Products R&D, Inc. |
Chronic Cluster Headache
|
January 17, 2017 | Phase 3 |
| NCT04458857 | Teva Branded Pharmaceutical Products R&D, Inc. |
Migraine
|
July 16, 2020 | Phase 3 |
Appearance
Liquid
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.